Notice: This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends FSDC vs. JANX, XENE, EWTX, FOLD, MRUS, ACAD, MOR, ZLAB, GMTX, and VERAShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Amicus Therapeutics (FOLD), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Zai Lab (ZLAB), Gemini Therapeutics (GMTX), and Vera Therapeutics (VERA). These companies are all part of the "medical" sector. FS Development vs. Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Amicus Therapeutics Merus ACADIA Pharmaceuticals MorphoSys Zai Lab Gemini Therapeutics Vera Therapeutics FS Development (NASDAQ:FSDC) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Does the media prefer FSDC or JANX? In the previous week, Janux Therapeutics had 5 more articles in the media than FS Development. MarketBeat recorded 5 mentions for Janux Therapeutics and 0 mentions for FS Development. Janux Therapeutics' average media sentiment score of 1.23 beat FS Development's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment FS Development Neutral Janux Therapeutics Positive Is FSDC or JANX more profitable? FS Development has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. FS Development's return on equity of 0.00% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets FS DevelopmentN/A N/A N/A Janux Therapeutics -463.91%-10.47%-9.86% Does the MarketBeat Community prefer FSDC or JANX? Janux Therapeutics received 40 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformFS DevelopmentN/AN/AJanux TherapeuticsOutperform Votes4070.18% Underperform Votes1729.82% Which has preferable valuation and earnings, FSDC or JANX? FS Development has higher earnings, but lower revenue than Janux Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFS DevelopmentN/AN/AN/AN/AN/AJanux Therapeutics$13.05M228.57-$58.29M-$1.17-48.57 Do insiders & institutionals have more ownership in FSDC or JANX? 89.8% of FS Development shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend FSDC or JANX? Janux Therapeutics has a consensus target price of $89.90, indicating a potential upside of 58.19%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryJanux Therapeutics beats FS Development on 9 of the 13 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$807.28M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E RatioN/A10.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / BookN/A5.094.784.78Net IncomeN/A$151.83M$120.23M$225.60M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$64.50+2.5%N/A+7.2%$807.28MN/A0.00N/AJANXJanux Therapeutics3.6708 of 5 stars$61.79+1.1%$89.90+45.5%+496.3%$3.24B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.7904 of 5 stars$41.30+3.1%$56.90+37.8%-5.8%$3.15B$9.43M-14.20251Insider TradeEWTXEdgewise Therapeutics2.722 of 5 stars$32.99+19.4%$42.33+28.3%+261.7%$3.12BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeFOLDAmicus Therapeutics4.3254 of 5 stars$9.83+5.0%$16.88+71.7%-23.7%$2.94B$493.67M-28.71480Analyst DowngradeMRUSMerus2.8078 of 5 stars$42.90+0.2%$85.64+99.6%+61.7%$2.94B$35.93M-10.8437ACADACADIA Pharmaceuticals3.8468 of 5 stars$17.22-0.2%$25.60+48.7%-41.9%$2.87B$726.44M22.13510MORMorphoSys0.127 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageZLABZai Lab1.7093 of 5 stars$26.05-1.1%$55.00+111.1%-7.4%$2.83B$355.75M-9.512,175GMTXGemini TherapeuticsN/A$64.89+1.0%N/A+10.4%$2.81BN/A-64.8930VERAVera Therapeutics3.481 of 5 stars$44.16+0.2%$59.22+34.1%+180.4%$2.80BN/A-16.8840Insider Trade Related Companies and Tools Related Companies Janux Therapeutics Competitors Xenon Pharmaceuticals Competitors Edgewise Therapeutics Competitors Amicus Therapeutics Competitors Merus Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Zai Lab Competitors Gemini Therapeutics Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FSDC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FSDC Stock Alerts